This agent has been assessed in phase II clinical trials (NCT00072748, NCT00072748) for patients with NSCLC or colorectal carcinoma.92 Moreover, the third-generation EGFR inhibitor furmonertinib (alflutinib) developed by Allist Pharmaceuticals is being evaluated for the treatment of NSCLC in several clinical trials (NCT02973763, NCT03452592, and NCT03787992). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.